Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Utility of a Second Interim Maintenance Phase to Improve Outcomes for Pediatric Acute Lymphoblastic Leukemia: A Report from the Children's Oncology Group

Blood (2024) 144 (Supplement 1): 2813.

https://doi.org/10.1182/blood-2024-194872

Published: 2024

Journal Articles

Additional Induction Intrathecal Cytarabine for Patients with CNS2 Disease at Diagnosis Is Not Beneficial for Patients with B-ALL Treated on Children's Oncology Group Protocols AALL0932 and AALL1131

Cathy A. Lee-Miller, John A. Kairalla, Emily Hibbitts, Naomi J. Winick, Anne Angiolillo, Reuven J. Schore, Wanda L. Salzer, Michael J. Burke, Mignon L. Loh, Elizabeth A. Raetz, Stephen P. Hunger, Meenakshi Devidas, David T. Teachey, Sumit Gupta, Jennifer L. McNeer

Blood (2024) 144 (Supplement 1): 4195.

https://doi.org/10.1182/blood-2024-203456

Published: 2024

Journal Articles

Prognostic Impact of t(1;19) in Pediatric B-Cell Acute Lymphoblastic Leukemia (B-ALL) Patients Treated on Contemporary Children's Oncology Group (COG) Protocols

Ashley Pinchinat, John A. Kairalla, Meenakshi Devidas, Andrew J. Carroll, Mary Shago, Anne Angiolillo, Michael J. Burke, Wanda L. Salzer, Naomi J. Winick, Mignon L. Loh, David T. Teachey, Elizabeth A. Raetz, Karen R Rabin, Rachel E. Rau, Sumit Gupta

Blood (2024) 144 (Supplement 1): 315.

https://doi.org/10.1182/blood-2024-198507

Published: 2024

Journal Articles

Feasibility and Outcome of Post-Induction Therapy Incorporating Dasatinib for Patients with Newly Diagnosed ABL-Class Fusion B-Lymphoblastic Leukemia (ABL-class Fusion B-ALL): Children's Oncology Group AALL1131

Blood (2023) 142 (Supplement 1): 961.

https://doi.org/10.1182/blood-2023-190495

Published: 2023

Journal Articles

Patients with Down Syndrome and High-Risk B-Acute Lymphoblastic Leukemia Demonstrate Improved Outcomes on a Modified Chemotherapy Regimen: A Report from Children's Oncology Group Study AALL1131

Vilmarie Rodriguez, Meenakshi Devidas, Zhiguo (Bruce) Chen, Andrew J Carroll, Nyla A. Heerema, Michael J. Borowitz, Brent L. Wood, William L. Carroll, Naomi J Winick, Elizabeth A. Raetz, Mignon L. Loh, Michael J. Burke, Wanda L. Salzer, Stephen P. Hunger, Karen R. Rabin

Blood (2023) 142 (Supplement 1): 824.

https://doi.org/10.1182/blood-2023-185368

Published: 2023

Journal Articles

The Impact of Cumulative Anesthesia Exposure on Neurocognitive Outcomes in Children with High-Risk Precursor B Acute Lymphoblastic Leukemia: A Multicenter Children's Oncology Group Study

Sarah Alexander, Sumit Gupta, John Kairalla, Emily Hibbitts, Hannah Weisman, Doralina Anghelescu, Naomi J Winick, Kevin R. Krull, Wanda L Salzer, Michael J. Burke, Lia Gore, Meenakshi Devidas, Stephen P. Hunger, Mignon L. Loh, Kristina Hardy

Blood (2022) 140 (Supplement 1): 2179–2180.

https://doi.org/10.1182/blood-2022-166765

Published: 2022

Journal Articles

Comparison of Current and Enhanced Risk Stratification of 21,199 Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia Using Objective Risk Categorization Criteria: A Children's Oncology Group Report

Blood (2021) 138 (Supplement 1): 2382.

https://doi.org/10.1182/blood-2021-148593

Published: 2021

Journal Articles

Racial, Ethnic, and Socioeconomic Factors Result in Disparities in Outcome Among Children with Acute Lymphoblastic Leukemia Not Fully Attenuated By Disease Prognosticators: A Children's Oncology Group (COG) Study

Blood (2021) 138 (Supplement 1): 211.

https://doi.org/10.1182/blood-2021-147386

Published: 2021

Journal Articles

Enhanced Risk Stratification of 21,178 Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia (ALL) Incorporating White Blood Count (WBC), Age, and Minimal Residual Disease (MRD) at Day 8 and 29 As Continuous Variables: A Children's Oncology Group (COG) Report

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-139081

Published: 2020

Journal Articles

Outcomes of Patients with Down Syndrome and CRLF2 -Overexpressing Acute Lymphoblastic Leukemia (ALL): A Report from the Children's Oncology Group (COG)

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-143165

Published: 2020

Journal Articles

Outcomes of Patients with CRLF2 -Overexpressing Acute Lymphoblastic Leukemia without Down Syndrome: A Report from the Children's Oncology Group

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-134327

Published: 2020

Journal Articles

The Genomic Landscape of Childhood Acute Lymphoblastic Leukemia

Kathryn G. Roberts, PhD, Samuel W. Brady, PhD, Zhaohui Gu, PhD, Lei Shi, PhD, Stanley Pounds, PhD, Deqing Pei, MS, Cheng Cheng, PhD, Yunfeng Dai, PhD, Meenakshi Devidas, PhD, Chunxu Qu, PhD, Ashley Hill, BS, Xiaotu Ma, Lei Wei, PhD, Sasi Arunachalam, PhD, Kohei Hagiwara, MD, Yangling Liu, Diane Flasch, Yu Liu, PhD, Matthew Parker, PhD, Xiaolong Chen, PhD, Yongjin Li, PhD, Yiping Fan, PhD, Robert Michael, PhD, Michael Rusch, BS, Mark Wilkinson, Scott Foy, PhD, Dale Hedges, PhD, Scott Newman, PhD, Xin Zhou, PhD, Jian Wang, Shalini C. Reshmi, PhD, Julie M. Gastier-Foster, PhD, Patee Gesuwan, Malcolm A Smith, MD PhD, Daniela S. Gerhard, PhD, Naomi Winick, MD, Andrew J. Carroll, PhD, Nyla A. Heerema, PhD, Richard C. Harvey, PhD, Cheryl L. Willman, MD, Eric Larsen, MD, Elizabeth A. Raetz, MD, Michael J. Borowitz, MD PhD, Brent L Wood, MD PhD, William L. Carroll, MD, Patrick A. Zweidler-McKay, MD PhD, Karen R. Rabin, MD PhD, Leonard A. Mattano, MD, Kelly Maloney, MD, Stuart S. Winter, MD, Michael J. Burke, MD, Wanda L. Salzer, MD, Kimberly P. Dunsmore, Anne Angiolillo, MD, Kristine R Crews, PharmD, James R. Downing, MD, Sima Jeha, MD, William E. Evans, PharmD, Ching-Hon Pui, MD, Jun J. Yang, PhD, Mary V. Relling, PharmD, Stephen P. Hunger, MD, Mignon L. Loh, MD, Jinghui Zhang, PhD, Charles G. Mullighan, MBBS, MD

Blood (2019) 134 (Supplement_1): 649.

https://doi.org/10.1182/blood-2019-124881

Published: 2019

Journal Articles

Triple Intrathecal Therapy (Methotrexate/Hydrocortisone/Cytarabine) Does Not Improve Disease-Free Survival Versus Intrathecal Methotrexate Alone in Children with High Risk B-Lymphoblastic Leukemia: Results of Children's Oncology Group Study AALL1131

Wanda L. Salzer, MD, Michael J. Burke, MD, Meenakshi Devidas, PhD, Lia Gore, MD, Joanne M. Hilden, MD, Eric Larsen, MD, Karen R. Rabin, MD PhD, Patrick A. Zweidler-McKay, MD PhD, Michael J. Borowitz, MD PhD, Brent Wood, MD PhD, Nyla A. Heerema, PhD, Andrew J. Carroll, PhD, Naomi Winick, MD, William L. Carroll, MD, Elizabeth A. Raetz, MD, Mignon L. Loh, MD, Stephen P. Hunger, MD

Blood (2018) 132 (Supplement 1): 35.

https://doi.org/10.1182/blood-2018-99-116180

Published: 2018

Journal Articles

Targetable kinase gene fusions in high-risk B-ALL: a study from the Children’s Oncology Group

Blood (2017) 129 (25): 3352–3361.

https://doi.org/10.1182/blood-2016-12-758979

Published: 2017

Includes: Supplemental data

Journal Articles

Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children’s Oncology Group study AALL0232

Michael J. Borowitz, Brent L. Wood, Meenakshi Devidas, Mignon L. Loh, Elizabeth A. Raetz, Wanda L. Salzer, James B. Nachman, Andrew J. Carroll, Nyla A. Heerema, Julie M. Gastier-Foster, Cheryl L. Willman, Yunfeng Dai, Naomi J. Winick, Stephen P. Hunger, William L. Carroll, Eric Larsen

Blood (2015) 126 (8): 964–971.

https://doi.org/10.1182/blood-2015-03-633685

Published: 2015

Includes: Supplemental data

Journal Articles

Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children’s Oncology Group

Wanda L. Salzer, Barbara Asselin, Jeffrey G. Supko, Meenakshi Devidas, Nicole A. Kaiser, Paul Plourde, Naomi J. Winick, Gregory H. Reaman, Elizabeth Raetz, William L. Carroll, Stephen P. Hunger

Blood (2013) 122 (4): 507–514.

https://doi.org/10.1182/blood-2013-01-480822

Published: 2013

Journal Articles

Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group

Joanne M. Hilden, Patricia A. Dinndorf, Sharon O. Meerbaum, Harland Sather, Doojduen Villaluna, Nyla A. Heerema, Ron McGlennen, Franklin O. Smith, William G. Woods, Wanda L. Salzer, Helen S. Johnstone, Zoann Dreyer, Gregory H. Reaman

Blood (2006) 108 (2): 441–451.

https://doi.org/10.1182/blood-2005-07-3011

Published: 2006

NARROW

Utility of a Second Interim Maintenance Phase to Improve Outcomes for Pediatric Acute Lymphoblastic Leukemia: A Report from the Children's Oncology Group

Additional Induction Intrathecal Cytarabine for Patients with CNS2 Disease at Diagnosis Is Not Beneficial for Patients with B-ALL Treated on Children's Oncology Group Protocols AALL0932 and AALL1131

Prognostic Impact of t(1;19) in Pediatric B-Cell Acute Lymphoblastic Leukemia (B-ALL) Patients Treated on Contemporary Children's Oncology Group (COG) Protocols

Feasibility and Outcome of Post-Induction Therapy Incorporating Dasatinib for Patients with Newly Diagnosed ABL-Class Fusion B-Lymphoblastic Leukemia (ABL-class Fusion B-ALL): Children's Oncology Group AALL1131

Patients with Down Syndrome and High-Risk B-Acute Lymphoblastic Leukemia Demonstrate Improved Outcomes on a Modified Chemotherapy Regimen: A Report from Children's Oncology Group Study AALL1131

The Impact of Cumulative Anesthesia Exposure on Neurocognitive Outcomes in Children with High-Risk Precursor B Acute Lymphoblastic Leukemia: A Multicenter Children's Oncology Group Study

Comparison of Current and Enhanced Risk Stratification of 21,199 Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia Using Objective Risk Categorization Criteria: A Children's Oncology Group Report

Racial, Ethnic, and Socioeconomic Factors Result in Disparities in Outcome Among Children with Acute Lymphoblastic Leukemia Not Fully Attenuated By Disease Prognosticators: A Children's Oncology Group (COG) Study

Enhanced Risk Stratification of 21,178 Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia (ALL) Incorporating White Blood Count (WBC), Age, and Minimal Residual Disease (MRD) at Day 8 and 29 As Continuous Variables: A Children's Oncology Group (COG) Report

Outcomes of Patients with Down Syndrome and CRLF2 -Overexpressing Acute Lymphoblastic Leukemia (ALL): A Report from the Children's Oncology Group (COG)

Outcomes of Patients with CRLF2 -Overexpressing Acute Lymphoblastic Leukemia without Down Syndrome: A Report from the Children's Oncology Group

The Genomic Landscape of Childhood Acute Lymphoblastic Leukemia

Triple Intrathecal Therapy (Methotrexate/Hydrocortisone/Cytarabine) Does Not Improve Disease-Free Survival Versus Intrathecal Methotrexate Alone in Children with High Risk B-Lymphoblastic Leukemia: Results of Children's Oncology Group Study AALL1131

Targetable kinase gene fusions in high-risk B-ALL: a study from the Children’s Oncology Group

Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children’s Oncology Group study AALL0232

Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children’s Oncology Group

Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only